Literature DB >> 2410062

Hematopoietic factor production by a cell line (TC-1) derived from adherent murine marrow cells.

Z X Song, R K Shadduck, D J Innes, A Waheed, P J Quesenberry.   

Abstract

An adherent cell line, termed TC-1, has been isolated from long-term liquid culture of murine marrow cells by repeated exposure of the adherent cells to 0.1% trypsin. This is an alkaline phosphatase-positive cell line showing variable staining with acid phosphatase and alpha-naphthyl acetate esterase. On electron microscopy, the cells have moderate amounts of rough endoplasmic reticulum and variable numbers of polyribosomes. Some cells contain large clusters of laked glycogen particles. Intermediate junctions are present between some cells. Conditioned medium from this cell line produced from 384 to 638 units of CSF-1 per milliliter by radioimmunoassay and a CSF-1-dependent synergistic activity, which stimulates giant macrophage colony formation of marrow cells in soft agar. The conditioned medium also stimulates 3H-TdR incorporation by marrow cells in liquid culture and induces secondary adherent cell lines. The growth factor(s) produced by the TC-1 stromal cell line may be important in the regulation of early stages of hematopoietic differentiation. Two subclones, TC-1-C-11 and TC-1-C-3, have been isolated from passage 25 of the TC-1 cells by a penicylinder separation technique. The TC-1-C-11 is phenotypically like the parent TC-1 line and produces macrophage growth factors. The TC-1-C-3 grows as an epithelioid monolayer with visible junctions among adjacent cells under phase contrast microscopy. This subclone produces retrovirus and is capable of providing anchorage support for hematopoietic stem cells. The TC-1 cell line and its subclones may provide models for the control of early stem cell proliferation and differentiation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2410062

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Bone marrow stromal cell changes in haematological malignancies.

Authors:  S A Dilly; C J Jagger
Journal:  J Clin Pathol       Date:  1990-11       Impact factor: 3.411

2.  Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow.

Authors:  M Chackal-Roy; C Niemeyer; M Moore; B R Zetter
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

3.  Recombinant tumor necrosis factor alpha and interleukin 1 alpha increase expression of c-abl protooncogene mRNA in cultured human marrow stromal cells.

Authors:  D F Andrews; J J Nemunaitis; J W Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  Hemopoietic growth factor production by a marrow adherent cell line.

Authors:  P J Quesenberry; P D Witte; K Landreth; Z X Song; H E McGrath; F M Stewart; Y X He; G B Baber; E Kleeman; D Innes
Journal:  Trans Am Clin Climatol Assoc       Date:  1986

5.  Expression of human bone-related proteins in the hematopoietic microenvironment.

Authors:  M W Long; J L Williams; K G Mann
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

6.  Secretion of insulinlike growth factor I and insulinlike growth factor-binding proteins by murine bone marrow stromal cells.

Authors:  S L Abboud; C R Bethel; D C Aron
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

7.  Regulation of macrophage alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein by lipopolysaccharide and interferon-gamma.

Authors:  J LaMarre; B B Wolf; E L Kittler; P J Quesenberry; S L Gonias
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

8.  Murine splenic hematopoietic subpopulations: the enlarged undifferentiated subset in New Zealand black mice is multipotent stem cells.

Authors:  V Manohar; K Huppi; E Lizzio; T Hoffman
Journal:  Clin Diagn Lab Immunol       Date:  1994-01

9.  Failure in generating hemopoietic stem cells is the primary cause of death from cytomegalovirus disease in the immunocompromised host.

Authors:  W Mutter; M J Reddehase; F W Busch; H J Bühring; U H Koszinowski
Journal:  J Exp Med       Date:  1988-05-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.